Drug interactions between antiretroviral therapy and biologic therapy in patients with HIV disease and rheumatoid arthritis: a narrative literature review
DOI:
https://doi.org/10.61182/rnavmed.v6n2a1Keywords:
HIV, rheumatoid arthritis, drug interactions, biologic therapyAbstract
The simultaneous presence of human immunodeficiency virus and rheumatoid arthritis in patients poses challenges for public health. From the pharmacological point of view, it is pertinent to observe the interactions between the drugs involved in treating them, little studied so far. This study proposes a narrative review of the medical literature in different databases, with publication filters such as time (1997-2013) and treatment of the central theme. Twenty-two articles with such characteristics were analyzed. The literature reviewed does not report interactions between drugs to treat rheumatoid arthritis and HIV. Studies are still needed to identify such drug-drug interactions.
References
Peña E, Prieto L, Cárdenas V. Terapia biológica para el tratamiento de pacientes con artritis reumatoide refractaria [Internet]. 2013 [citado el 28 de noviembre de 2019]. Disponible en: https://docs.bvsalud.org/biblioref/2017/11/875718/biologicos_ar_11022014-vf.pdf
DeSimone JA. Inflammatory Reactions in HIV-1–Infected Persons after Initiation of Highly Active Antiretroviral Therapy. Ann Intern Med. 2000;133(6):447–54. https://doi.org/10.7326/0003-4819-133-6-200009190-00013
Walker UA, Tyndall A, Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology. 2008;47(7):952–9. https://doi.org/10.1093/rheumatology/ken132
Reveille JD, Williams FM. Rheumatologic complications of HIV infection. Best Pract Res Clin Rheumatol. 2006;20(6):1159–79. https://doi.org/10.1016/j.berh.2006.08.015
Cohen O, FA WD. The immunopathogenesis of HIV infection. En: Paul W, editor. Fundamental Immunology. 4a ed. Philadelphia: Lippincott-Raven Publishers; 1999. p. 1455–98.
Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1. Science (1979). 1996;272(5270):1955–8. https://doi.org/10.1126/science.272.5270.1955
Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor. Science (1979). 1996;272(5263):872–7. https://doi.org/10.1126/science.272.5263.872
Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey). AIDS. 2014;28(8):1181–91. https://doi.org/10.1097/qad.0000000000000222
Morlat P (Ed.). Prise en charge du VIH – Recommandations du groupe d’experts [Internet]. Recommandations du groupe d’experts. Paris: CNS & ANRS; 2017. Disponible en: www.cns.sante.fr/wp-content/uploads/2017/10/experts-vih_cancers.pdf
Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet. 2008;372(9635):293–9. https://doi.org/10.1016/s0140-6736(08)61113-7
UNAIDS. Global Report [Internet]. Geneva: World Health Organization; 2012 [citado el 28 de noviembre de 2019]. Disponible en: https://www.unaids.org/sites/default/files/media_asset/20121120_UNAIDS_Global_Report_2012_with_annexes_en_1.pdf
Ministerio de Salud y Protección Social & Fondo de Población de las Naciones Unidas. Guía de práctica clínica (GPC) basada en la evidencia científica para la atención de la infección por VIH/Sida en adolescentes (con 13 años de edad o más) y adultos [Internet]. Bogotá: UNFPA; 2014 [citado el 28 de noviembre de 2019]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/gpc-completa-evidencia-cientifica-vih-sida-adolescentes-adultos.pdf
Tuset M, Miró JM, Codina CRJ. Guía de interacciones farmacológicas en VIH. Barcelona: Aurores y Bristol-Myers; 2002.
Tuset M, Miró JM, Codina C, Blanco J. L, Soy D, Sarasa M. Interacciones de los fármacos antirretrovirales. En: Gatell JM, Clotet B, Mallolas J, Miró JM, Podzamczer D, editores. Guía práctica del sida: clínica, diagnóstico y tratamiento. Barcelona: Ediciones Masson; 2002. p. 555–93.
Escobar I, Ortega L (Coord.). 5° Seminario de Atención Farmacéutica: Ponencias. Madrid: SEFH; 2005.
Tuset M. Interacciones medicamentosas entre los antirretrovirales y los antituberculosos. Rev Esp Sanid Penit. 1999;1(4):28–44.
Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica D, et al. Human Lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res. 1985;13(17):6361–73. https://doi.org/10.1093%2Fnar%2F13.17.6361
Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392(6676):565–8. https://doi.org/10.1038/33340
Salgado E, Maneiro JR. Nuevos tratamientos en artritis reumatoide. Med Clin (Barc). 2014;143(10):461–6.
European Medicines Agency. Humira (adalimumab) [Internet]. Amsterdam; 2020 [citado el 28 de noviembre de 2019]. Disponible en: https://www.ema.europa.eu/en/documents/overview/humira-epar-medicine-overview_es.pdf
Tornero Molina J, Ballina García FJ, Calvo Alén J, Caracuel Ruiz MÁ, Carbonell Abelló J, López Meseguer A, et al. Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración. Reumatol Clin. 2015;11(1):3–8.
Ramos A. Infecciones en el paciente inmunodeficiente. ¿Qué papel tienen los fármacos? Reumatol Clin. 2008;4:1–6.
León Regal ML, Alvarado Borges A, De Armas García JO, Miranda Alvarado L, Varens Cedeño JA, Cuesta del Sol JÁ. Respuesta inflamatoria aguda. Consideraciones bioquímicas y celulares. Revista Finlay [Internet]. 2015 [citado el 28 de noviembre de 2019];5(1):47–62. Disponible en: http://scielo.sld.cu/scielo.php?pid=S2221-24342015000100006&script=sci_arttext
Pasut G. Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol. BioDrugs. 2014;28(S1):15–23.
Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13(11):1323–32. https://doi.org/10.1002/ibd.20225
Howson JMM, Walker NM, Clayton D, Todd JA. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA‐B and HLA‐A. Diabetes Obes Metab. 2009;11(s1):31–45.
Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis. PLoS One. 2012;7(1):1–14.
Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology. 2011;50(3):437–49. https://doi.org/10.1093/rheumatology/keq287
Boyd M, Pett S. Experimental and clinical pharmacology: HIV fusion inhibitors: a review. Aust Prescr. 2008;31(3):66–9.
Beaird SL. HMG-CoA Reductase Inhibitors: Assessing Differences in Drug Interactions and Safety Profiles. Journal of the American Pharmaceutical Association (1996). 2000;40(5):637–44.
Herman RJ. Drug interactions and the statins. CMAJ. 1999;161(10):1281–6. https://pubmed.ncbi.nlm.nih.gov/10584091
Frassetto LA, Baloum M, Roland ME, Carlson L, Stock PBL. Two-year Evaluation of the Interactions between Antiretroviral Medication and Cyclosporine in HIV+ Liver and Kidney Transplant Recipients (abstract 540). En: 10th Conference on Retroviruses and Opportunistic Infections. Boston: CROI; 2003.
Schvarcz R, Rudbeck G, Söderdahl G, Ståhle L. Interaction between Nelfinavir and Tacrolimus After Orthoptic Liver Transplantation in a Patient Coinfected with HIV And Hepatitis C Virus (HCV). Transplantation. 2000;69(10):2194–5. https://doi.org/10.1097/00007890-200005270-00041
Gerber JG, Rosenkranz S, Segal Y, Aberg J, D’Amico R, Mildvan D, et al. Effect of Ritonavir/Saquinavir on Stereoselective Pharmacokinetics of Methadone: Results of AIDS Clinical Trials Group (ACTG) 401. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2001;27(2):153–60. https://doi.org/10.1097/00126334-200106010-00010
Moreno S, Podzamczer D, Blázquez R, Iribarren JA, Ferrer E, Reparaz J, et al. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. AIDS. 2001;15(9):1185–7. https://doi.org/10.1097/00002030-200106150-00018
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Linda Estefanía Navarrete Motta
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.